^
    Back
    Association details:
    Biomarker:KRAS mutation + PD-L1 expression
    Cancer:Colorectal Cancer
    Drug:bintrafusp alfa (M7824) (PD-L1 inhibitor, TGFβ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    The Oncologist
    Title:

    Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial

    Published date:
    12/28/2022
    Excerpt:
    The patient with a PR had a fresh biopsy taken within 7 days before treatment start and was found to have KRAS mutant MSS CRC and CRC consensus molecular subtype 4 (CMS4)...This patient had the highest tumor cell PD-L1 expression (20%) amongst the 32 patients, completed 100 weeks of treatment with bintrafusp alfa, and had a duration of response of 8.3 months...
    DOI:
    https://doi.org/10.1093/oncolo/oyac254